Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00717457 · ClinicalTrials.gov registry record · Phase 3
A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.
A Phase 3 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,189
- Enrollment target
NCT00717457: Completed Phase 3 study, sponsored by Hoffmann-La Roche.
NCT00717457 is a Phase 3 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 1,189 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (54% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00717457, a Phase 3 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,189 participants
- Enrollment target
Study Summary
This 3-arm study will assess the efficacy, safety and tolerability of taspoglutide compared with exenatide in patients with type 2 diabetes mellitus inadequately controlled with metformin, thiazolidinedione or a combination of both. Patients will be randomized to receive taspoglutide (10mg once weekly or 10mg once weekly for 4 weeks followed by 20mg once weekly) or exenatide (5 micrograms twice daily for 4 weeks followed by 10 micrograms twice daily) in a ratio of 1:1:1 in addition to continued prestudy metformin and thiazolidinedione either alone or in combination. The anticipated time on study treatment is 3+ years, and the target sample size is \>500 individuals.
Interventions
- DRUG exenatide
- DRUG taspoglutide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,189 participants |
| Start Date | 2008-07 |
| Est. Completion | 2011-03 |
| Phase | Phase 3 |
What the finished NCT00717457 record still lists
NCT00717457 is an interventional study that assigns participants to a tested intervention. Its 1,189 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (54% higher).
The record links to 0 conditions, and to 2 interventions - of which exenatide is the first listed.
NCT00717457 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00717457 about?
NCT00717457 is a clinical study titled "A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.". This 3-arm study will assess the efficacy, safety and tolerability of taspoglutide compared with exenatide in patients with type 2 diabetes mellitus inadequately controlled with metformin, thiazolidinedione or a combination of both. Patients will be randomized to receive taspoglutide (10mg once week...
What is the current status of trial NCT00717457?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,189 participants. The study started on 2008-07. Estimated completion is 2011-03.
What interventions are being tested in trial NCT00717457?
The interventions under investigation include: exenatide (DRUG), taspoglutide (DRUG).
Who is sponsoring clinical trial NCT00717457?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00717457's enrollment target sits among peer trials
1,189 229th of 2000 higher than 1,772 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05580419 · 1,188 participants · NA
Impact of 4PCP on Practitioner and Patient Outcomes
- NCT06290869 · 1,188 participants · Phase 3
Tobacco Education and Lung Health Study (TEAL)
- NCT04293562 · 1,186 participants · Phase 3
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
- NCT07177339 · 1,196 participants · Phase 3
eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia